Acurion

Triple-negative breast cancer (TNBC) accounts for 10–15% of breast cancer diagnoses in the United States, with an estimated 31,000 to 47,000 new cases annually.

Acurion’s OncoGaze connects ovarian cancer patients to precision therapies faster.

OncoGaze speeds up HRD detection from pathology slides, reducing delays in next-generation sequencing and enabling earlier treatment decisions for patients.

HRD detection is challenging for traditional next-generation sequencing (NGS) methods, often requiring large tissue samples and resulting in delays or inconclusive findings.

Funding led by TK Partners supports further clinical validation, regulatory preparation, and commercialization of OncoGaze.

Acurion offers a demo of its OncoGaze platform for precision cancer care.

Acurion aims to deliver precision medicine to cancer patients faster, supported by a leadership team of oncologists, scientists, and life science leaders.

Leandra leads strategic partnerships and programs at Acurion, with over nine years of experience in commercial execution across the life sciences sector.

As the Chief Scientific Officer at Acurion, Dr. Alexandrov brings his extensive expertise to the forefront of precision oncology. His leadership is instrumental in advancing Acurion's mission to transform cancer diagnostics through clinically grounded innovation.

As CEO of Acurion, Inc., Rick leads a seasoned and diverse leadership team, guiding the company through key regulatory milestones and into commercial growth. A proven executive, Rick brings a strong track record of scaling both nonprofit and for-profit organizations.

Acurion’s OncoGaze platform uses AI to analyze pathology slides and detect cancer-related molecular biomarkers, such as homologous recombination deficiency (HRD).

Acurion's OncoGaze technology delivers critical genomic insights at the biopsy stage, empowering oncologists to make precision therapy a reality for more patients.